XML 56 R41.htm IDEA: XBRL DOCUMENT v3.25.0.1
Business Segment and Geographic Areas (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Revenue from External Customers by Geographic Areas and Product Line These product lines' net sales and primary geographic market where the products are sold, are as follows for the years ended December 31, 2024, 2023 and 2022:
 
2024
 Orthopedic SurgeryGeneral SurgeryTotal
Primary Geographic Markets
United States$210,670 $537,554 $748,224 
Europe, Middle East & Africa132,106 110,958 243,064 
Asia Pacific119,766 74,918 194,684 
Americas (excluding the United States)81,446 39,597 121,043 
Total sales from contracts with customers$543,988 $763,027 $1,307,015 
2023
 Orthopedic SurgeryGeneral SurgeryTotal
Primary Geographic Markets
United States$199,568 $500,592 $700,160 
Europe, Middle East & Africa127,637 98,616 226,253 
Asia Pacific123,043 74,358 197,401 
Americas (excluding the United States)82,910 38,020 120,930 
Total sales from contracts with customers$533,158 $711,586 $1,244,744 
2022
 Orthopedic SurgeryGeneral SurgeryTotal
Primary Geographic Markets
United States$173,176 $405,777 $578,953 
Europe, Middle East & Africa113,649 84,288 197,937 
Asia Pacific103,353 59,124 162,477 
Americas (excluding the United States)71,350 34,755 106,105 
Total sales from contracts with customers$461,528 $583,944 $1,045,472 
Schedule of Segment Reporting Information, by Segment
The following table includes significant segment expenses for the years ended December 31, 2024, 2023 and 2022:

Years Ended
December 31,
 202420232022
Net sales
$1,307,015 $1,244,744 $1,045,472 
Cost of sales
573,983 568,499 474,227 
Salesforce and commission expense
225,886 215,799 186,596 
Marketing expense
65,338 60,918 56,027 
Distribution expense
50,183 53,701 44,874 
General and administrative expense
117,463 111,235 96,108 
Stock-based compensation expense
25,558 24,257 21,729 
Amortization expense
28,629 29,068 27,791 
Non-cash adjustments to fair value of contingent consideration liability(41,048)(2,421)2,518 
Research and development expense
54,426 52,602 47,152 
Interest expense
37,297 39,775 28,905 
Loss on convertible notes and related hedge transactions(b)
— — 112,011 
Provision for income taxes
30,606 16,369 9,720 
Other segment items(a)
6,271 10,483 18,396 
Net income (loss)
$132,423 $64,459 $(80,582)